These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19148580)

  • 1. INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model.
    Graeser R; Esser N; Unger H; Fichtner I; Zhu A; Unger C; Kratz F
    Invest New Drugs; 2010 Feb; 28(1):14-9. PubMed ID: 19148580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials.
    Kratz F
    Expert Opin Investig Drugs; 2007 Jun; 16(6):855-66. PubMed ID: 17501697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with the albumin-binding prodrug of doxorubicin (INNO-206) and doxorubicin achieves complete remissions and improves tolerability in an ovarian A2780 xenograft model.
    Kratz F; Fichtner I; Graeser R
    Invest New Drugs; 2012 Aug; 30(4):1743-9. PubMed ID: 21590366
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of combination therapy schedules of doxorubicin and an acid-sensitive albumin-binding prodrug of doxorubicin in the MIA PaCa-2 pancreatic xenograft model.
    Kratz F; Azab S; Zeisig R; Fichtner I; Warnecke A
    Int J Pharm; 2013 Jan; 441(1-2):499-506. PubMed ID: 23149257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin.
    Abu Ajaj K; Graeser R; Kratz F
    Breast Cancer Res Treat; 2012 Jul; 134(1):117-29. PubMed ID: 22228402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound.
    Kratz F; Warnecke A; Scheuermann K; Stockmar C; Schwab J; Lazar P; Drückes P; Esser N; Drevs J; Rognan D; Bissantz C; Hinderling C; Folkers G; Fichtner I; Unger C
    J Med Chem; 2002 Dec; 45(25):5523-33. PubMed ID: 12459020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin.
    Kratz F; Ehling G; Kauffmann HM; Unger C
    Hum Exp Toxicol; 2007 Jan; 26(1):19-35. PubMed ID: 17334177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-myeloma effects of the novel anthracycline derivative INNO-206.
    Sanchez E; Li M; Wang C; Nichols CM; Li J; Chen H; Berenson JR
    Clin Cancer Res; 2012 Jul; 18(14):3856-67. PubMed ID: 22619306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin.
    Unger C; Häring B; Medinger M; Drevs J; Steinbild S; Kratz F; Mross K
    Clin Cancer Res; 2007 Aug; 13(16):4858-66. PubMed ID: 17699865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer.
    Dineen SP; Sullivan LA; Beck AW; Miller AF; Carbon JG; Mamluk R; Wong H; Brekken RA
    BMC Cancer; 2008 Nov; 8():352. PubMed ID: 19038046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.
    Schmid B; Chung DE; Warnecke A; Fichtner I; Kratz F
    Bioconjug Chem; 2007; 18(3):702-16. PubMed ID: 17378599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP).
    Graeser R; Chung DE; Esser N; Moor S; Schächtele C; Unger C; Kratz F
    Int J Cancer; 2008 Mar; 122(5):1145-54. PubMed ID: 17973264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo efficacy of acid-sensitive transferrin and albumin doxorubicin conjugates in a human xenograft panel and in the MDA-MB-435 mamma carcinoma model.
    Kratz F; Roth T; Fichiner I; Schumacher P; Fiebig HH; Unger C
    J Drug Target; 2000; 8(5):305-18. PubMed ID: 11328658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo evaluation of a novel albumin-binding prodrug of doxorubicin in an orthotopic mouse model of prostate cancer (LNCaP).
    Elsadek B; Graeser R; Esser N; Schäfer-Obodozie C; Tsurumi C; Abu Ajaj K; Warnecke A; Unger C; Saleem T; Kratz F
    Prostate Cancer Prostatic Dis; 2011 Mar; 14(1):14-21. PubMed ID: 21042336
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Cornillie J; Wozniak A; Pokreisz P; Casazza A; Vreys L; Wellens J; Vanleeuw U; Gebreyohannes YK; Debiec-Rychter M; Sciot R; Hompes D; Schöffski P
    Mol Cancer Ther; 2017 Aug; 16(8):1566-1575. PubMed ID: 28566438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer.
    Awasthi N; Zhang C; Schwarz AM; Hinz S; Wang C; Williams NS; Schwarz MA; Schwarz RE
    Carcinogenesis; 2013 Oct; 34(10):2361-9. PubMed ID: 23803690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
    Horiuchi T; Uwagawa T; Shirai Y; Saito N; Iwase R; Haruki K; Shiba H; Ohashi T; Yanaga K
    J Surg Res; 2016 Nov; 206(1):1-8. PubMed ID: 27916347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models.
    Higgins B; Kolinsky K; Smith M; Beck G; Rashed M; Adames V; Linn M; Wheeldon E; Gand L; Birnboeck H; Hoffmann G
    Anticancer Drugs; 2004 Jun; 15(5):503-12. PubMed ID: 15166626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression.
    Guo Z; Wang F; Di Y; Yao L; Yu X; Fu D; Li J; Jin C
    Int J Nanomedicine; 2018; 13():4869-4880. PubMed ID: 30214194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of doxorubicin α-linolenic acid conjugate and evaluation of its antitumor activity.
    Liang CH; Ye WL; Zhu CL; Na R; Cheng Y; Cui H; Liu DZ; Yang ZF; Zhou SY
    Mol Pharm; 2014 May; 11(5):1378-90. PubMed ID: 24720787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.